Serum lipoprotein(a) level is related to thrombin generation and spontaneous intermittent coronary occlusion in patients with acute myocardial infarction

Circulation

Volumn 94, Issue 9, 1996, Pages 2072-2076

  Haider, Agha W ^a,d   Andreotti, Felicita ^c   Thompson, Gilbert R ^a   Kluft, Cornelis ^b   Maseri, Attilio ^c   Davies, Graham J ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b TNO   (Netherlands)

^c CATHOLIC UNIVERSITY   (Italy)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

coagulation; fibrinolysis; lipoproteins; myocardial infarction; occlusion; thrombosis

Indexed keywords

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY THROMBOSIS; CORONARY RISK; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0029823742     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.9.2072     Document Type: Article

References (40)

1. De Wood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 1980;303:897-902.
2. Davies MJ, Woolf N, Robertson WB. Pathology of acute myocardial infarction with particular reference to occlusive coronary thrombi. Br Heart J. 1976;38:659-664.
3. Davies GJ, Chierchia S, Maseri A. Prevention of myocardial infarction by very early treatment with intracoronary streptokinase; some clinical observations. N Engl J Med. 1984;311:1488-1492.
4. Hackett D, Davies G, Chierchia S, Maseri A. Intermittent coronary occlusion in acute myocardial infarction: value of combined thrombolytic and vasodilator therapy. N Engl J Med. 1987;317:1055-1059.
5. Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature. 1989;339:301-303.
6. Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature. 1989;339:303-305.
7. Moliterno DJ, Lange RA, Meidell RS, Willard JE, Leffert CC, Gerard RD, Boerwinkle E, Hobbs HH, Hillis LD. Relation of plasma lipoprotein(a) to infarct artery patency in survivors of myocardial infarction. Circulation. 1993;88:935-940.
8. Hogg KJ, Hornung RS, Howie CA, Hockings N, Dunn FG, Hillis WS. Electrocardiographic prediction of coronary artery patency after thrombolytic treatment in acute myocardial infarction: use of the ST segment as a non invasive marker. Br Heart J. 1988;60:275-280.
9. Dagen MM, Packard CJ, Shepherd JA. Comparison of commercial kits for the measurement of lipoprotein (a). Ann Clin Biochem. 1991;28:359-364.
10. Clauss A. Rapid physiological coagulation method in determination of fibrinogen. Acta Haematol. 1957;17:237-246.
11. Ingerslev J. A sensitive ELISA for von Willebrand factor (vWf:Ag). Scand J Clin Lab Invest. 1987;47:143-149.
12. The TIMI Study Group. The thrombolysis in myocardia infarction (TIMI) trial: phase 1 findings. N Engl J Med. 1984;33:523-530.
13. Jeremy RW, Hackworthy RA, Bautovich G, Mutton BF, Harris PJ. Infarct artery perfusion and changes in left ventricular volume in the month after acute myocardial infarction. J Am Coll Cardiol. 1987;9: 989-995.
14. de Feyter PJ, van Eenige MJ, van der Wall EE, Bezemer PD, van Engelen CLJ, Funke-Kupper AJ, Kerkkamp HJ, Visser FC, Roos JP. Effects of spontaneous and streptokinase-induced recanalization on left ventricular function after myocardial infarction. Circulation. 1983;67:1039-1044.
15. Andreotti F, Roncaglioni MC, Hackett DR, Khan MI, Regan T. Haider AW, Davies GJ, Kluft C, Maseri A. Early coronary reperfusion blunts the procoagulant response of plasminogen activator inhibitor-1 and von Willebrand factor in acute myocardial infarction. J Am Coll Cardiol. 1990;16:1553-1560.
16. White HD, Morris RM, Brown MA, Takayama M, Maslowski A, Bass NM, Ormiston JA, Whitiock T. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med. 1987;317:850-855.
17. Gruppo Italian per lo Studio della Streptochinasi nell'Infarto miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;327:397-402.
18. Huber K, Rose D, Resch I, Schuster E, Glogar DH, Kaindl F, Binder BR, Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction. Thromb Haemost. 1988;60:372-376.
19. Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985;313:15571563.
20. Arnesen H, Semb G, Hol R, Karlsen H. Fibrinolytic capacity after venous stasis in patients undergoing aorto-coronary by-pass surgery: relation to shunt occlusion. Scand J Haematol. 1983;30(suppl 39):43-46.
21. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WRS, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and cardiovascular death: early results of a prospective study. Lancet. 1980;1:1050-1054.
22. Haider AW, Andreotti F, Hackett DR, Tousoulis D, Kluft C, Maseri A, Davies GJ. Early spontaneous intermittent myocardial reperfusion during acute myocardial infarction is associated with augmented thrombogenic activity and less myocardial damage. J Am Coll Cardiol. 1995;26:662-667.
23. Albers JJ, Marcovina SM, Lodge MS. The unique lipoprotein(a): properties and immunochemical measurement. Clin Chem. 1990;36: 2019-2026.
24. Heinrich J, Sandkamp M, Kokott R, Schulte H, Assmann G. Relationship of lipoprotein(a) to variables of coagulation and fibrinolysis in a healthy population. Clin Chem. 1991;37:1950-1954.
25. Guyton JR, Dahlen GH, Patsch W, Kautz JA, Gotto AM Jr. Relationship of plasma lipoprotein Lp(a) levels to race and to apolipoprotein B. Arteriosclerosis. 1985;5:265-272.
26. Parra HJ, Luyeye I, Bouramoue C, Demarquilly C, Fruchart JC. Black-white differences in serum Lp(a) lipoprotein levels. Clin Chim Acta. 1987;168:27-31.
27. Srinivasan SR, Dahlen GH, Jarpa RA, Webber LS, Berenson GS. Racial (black-white) differences in serum lipoprotein (a) distribution and its relation to parental myocardial infarction in children: Bogalusa Heart Study. Circulation. 1991;84:160-167.
28. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM. Human apolipoprotein(a): cDNA sequence of apolipoprotein homologous to plasminogen. Nature. 1987;330:132-137.
29. Utermann G. The mysteries of lipoprotein(a). Science. 1989;246: 904-910.
30. Dahlen G, Ericson C, Berg K. In vitro studies of the interaction of calcium ions and other divalent cations with the Lp(a) lipoprotein and other isolated serum lipoproteins. Clin Genet. 1978;14:115-124.
31. Simon DI, Fless GM, Scanu AM, Loscalzo J. Tissue type plasminogen activator binds to and is inhibited by surface bound lipoprotein(a) and low density lipoprotein. Biochemistry. 1991;30: 6671-6677.
32. Mao SJ, Tucci MA. Lipoprotein(a) enhances plasma clot lysis in vitro. FEBS Lett. 1990;267:131-134.
33. Savcic M, Hauert J, Vogt P, Kappenberger L, Bachmann F. High levels of PAI-1 and low levels of lipoprotein(a) deleterious in thrombolysis for myocardial infarction? J Am Coll Cardiol. 1994;23:79A. Abstract.
34. MBewu AD, Durrington PN, Mackness MI, Hunt L, Turkic WH, Creamer JE. Serum Lp(a) lipoprotein concentration and outcome of thrombolytic treatment for myocardial infarction. Br Heart J. 1994;71:316-321.
35. Ridker PM, Hennekens CH, Stamfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA. 1993;270:2195-2199.
36. Jauhiainen M, Koskinen P, Ehnholm C, Frick MH, Manttari M, Manninen V, Huttunen JK. Lipoprotein(a) and coronary heart disease risk: a nested case control study of the Helsinki Heart study participants. Atherosclerosis. 1991;89:59-67.
37. Cremer P, Nagel D, Labrot NB, Mann H, Muche R, Elster H, Siedel D. Lipoprotein(a) as a predictor of acute myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Gottingen risk incidence and prevalence study. Eur J Clin Invest. 1994;24:444-453.
38. Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis CE. Lipoprotein (a) levels and risk of coronary heart disease in men: the lipid research clinics coronary primary prevention trial. JAMA. 1994;271:999-1003.
39. Thompson GR, Maher VMG, Matthews S, Kitano Y, Neuwirth C, Shortt MB, Davies G, Rees A, Mir A, Prescott RJ, de Feyter P, Henderson A. Familial hypercholesterolaemia regression study: a randomised trial of low-density-lipoprotein apheresis. Lancet. 1995;345:811-816.
40. Williams JK, Bellinger DA, Nichols TC, Griggs TR, Bumol TF, Fouts RL, Clarkson TB. Occlusive arterial thrombosis in cynomolgus monkeys with varying plasma concentrations of lipoprotein(a). Arterioscler Thromb. 1993;13:548-554.